Serina Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $130K+132.1% YoYTTM through 30 Jun 2026
Net Income -$19.2MTTM through 30 Jun 2026
Free Cash Flow -$21.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -18,478.5% |
| Net Margin | -14,755.4% |
Returns
-221.9%ROE
-74.3%ROA
Balance Sheet Health
Debt / Equity0.19x
Current Ratio4.18x
Net Debt-$21.2Mnet cash position
Cash & Equivalents$23M
Quality Metrics
Altman Z-Score-4.88
Piotroski F-Score2 / 9
FCF Margin-16,308.5%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $130K
Diluted EPS-$1.87TTMFY2025: $-1.88
Dividend
No dividend
Capital Allocation
R&D Spend$14.1M
Capex Intensity50.8%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.